Search arXiv⌕ Search
Home/Archive/arXiv

arXiv · 2410.14433

A Bioinformatic Approach Validated Utilizing Machine Learning Algorithms to Identify Relevant Biomarkers and Crucial Pathways in Gallbladder Cancer

Rabea Khatun·Wahia Tasnim·Maksuda Akter·Md Manowarul Islam·Md. Ashraf Uddin·Md. Zulfiker Mahmud·Saurav Chandra Das
View original source ↗Read source document ↗Export metadata ↓

Abstract

Gallbladder cancer (GBC) is the most frequent cause of disease among biliary tract neoplasms. Identifying the molecular mechanisms and biomarkers linked to GBC progression has been a significant challenge in scientific research. Few recent studies have explored the roles of biomarkers in GBC. Our study aimed to identify biomarkers in GBC using machine learning (ML) and bioinformatics techniques. We compared GBC tumor samples with normal samples to identify differentially expressed genes (DEGs) from two microarray datasets (GSE100363, GSE139682) obtained from the NCBI GEO database. A total of 146 DEGs were found, with 39 up-regulated and 107 down-regulated genes. Functional enrichment analysis of these DEGs was performed using Gene Ontology (GO) terms and REACTOME pathways through DAVID. The protein-protein interaction network was constructed using the STRING database. To identify hub genes, we applied three ranking algorithms: Degree, MNC, and Closeness Centrality. The intersection of hub genes from these algorithms yielded 11 hub genes. Simultaneously, two feature selection methods (Pearson correlation and recursive feature elimination) were used to identify significant gene subsets. We then developed ML models using SVM and RF on the GSE100363 dataset, with validation on GSE139682, to determine the gene subset that best distinguishes GBC samples. The hub genes outperformed the other gene subsets. Finally, NTRK2, COL14A1, SCN4B, ATP1A2, SLC17A7, SLIT3, COL7A1, CLDN4, CLEC3B, ADCYAP1R1, and MFAP4 were identified as crucial genes, with SLIT3, COL7A1, and CLDN4 being strongly linked to GBC development and prediction.

Explore related subjects

q-bio.GNcs.LG

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Rabea Khatun, Wahia Tasnim, Maksuda Akter, Md Manowarul Islam, Md. Ashraf Uddin, Md. Zulfiker Mahmud, Saurav Chandra Das. 2024-10-18. A Bioinformatic Approach Validated Utilizing Machine Learning Algorithms to Identify Relevant Biomarkers and Crucial Pathways in Gallbladder Cancer. https://arxiv.org/abs/2410.14433

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related papers

arXiv2026

Revolutionizing Genomics with Reinforcement Learning Techniques

In recent years, Reinforcement Learning (RL) has emerged as a powerful tool for solving a wide range of problems, including decision-making and genomics. The exponential growth of raw genomic data over the past two decades has exceeded the capacity of manual analysis, leading to a growing interest in automatic data analysis and processing. RL algorithms are capable of learning from experience with minimal human supervision, making them well-suited for genomic data analysis and interpretation. One of the key benefits of using RL is the reduced cost associated with collecting labeled training data, which is required for supervised learning. While there have been numerous studies examining the applications of Machine Learning (ML) in genomics, this survey focuses exclusively on the use of RL in various genomics research fields, including gene regulatory networks (GRNs), genome assembly, and sequence alignment. We present a comprehensive technical overview of existing studies on the application of RL in genomics, highlighting the strengths and limitations of these approaches. We then discuss potential research directions that are worthy of future exploration, including the development of more sophisticated reward functions as RL heavily depends on the accuracy of the reward function, the integration of RL with other machine learning techniques, and the application of RL to new and emerging areas in genomics research. Finally, we present our findings and conclude by summarizing the current state of the field and the future outlook for RL in genomics.

q-bio.GN↗
arXiv2026

Transcriptomic Models for Immunotherapy Response Prediction Show Limited Cross-cohort Generalisability

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy; yet substantial proportion of patients exhibit intrinsic or acquired resistance, making accurate pre-treatment response prediction a critical unmet need. Transcriptomics-based biomarkers derived from bulk and single-cell RNA sequencing (scRNA-seq) offer a promising avenue for capturing tumour-immune interactions, yet the cross-cohort generalisability of existing prediction models remains unclear.We systematically benchmark nine state-of-the-art transcriptomic ICI response predictors, five bulk RNA-seq-based models (COMPASS, IRNet, NetBio, IKCScore, and TNBC-ICI) and four scRNA-seq-based models (PRECISE, DeepGeneX, Tres and scCURE), using publicly available independent datasets unseen during model development. Overall, predictive performance was modest: bulk RNA-seq models performed at or near chance level across most cohorts, while scRNA-seq models showed only marginal improvements. Pathway-level analyses revealed sparse and inconsistent biomarker signals across models. Although scRNA-seq-based predictors converged on immune-related programs such as allograft rejection, bulk RNA-seq-based models exhibited little reproducible overlap. PRECISE and NetBio identified the most coherent immune-related themes, whereas IRNet predominantly captured metabolic pathways weakly aligned with ICI biology. Together, these findings demonstrate the limited cross-cohort robustness and biological consistency of current transcriptomic ICI prediction models, underscoring the need for improved domain adaptation, standardised preprocessing, and biologically grounded model design.

q-bio.GN↗
arXiv2026

Large Language Model Agents for Evidence Based Genetic Disease Severity Classification

Disease severity classification for genetic conditions is subjective and labor-intensive, creating bottlenecks in genomic screening, where commercial panels vary widely in size and overlap. We developed an autonomous AI agent integrating Reasoning and Acting (ReAct) with Retrieval-Augmented Generation (RAG) to classify 10,211 Human Phenotype Ontology terms. It uses American College of Medical Genetics (ACMG)-endorsed severity guidelines and American College of Obstetricians and Gynecologists (ACOG) quality-of-life criteria to retrieve PubMed literature, generate interpretable reasoning chains, and independently verify claims. At the phenotype level, using expert-curated cohorts, the agent achieved 93.55% accuracy (MCC 0.9237) with 82.6% to 91.4% of claims supported by direct evidence or valid inferences. Gene-level severity was aggregated across 8,738 pairs, identifying 3,283 autosomal recessive pairs with severe or profound presentations. External validation showed 95.2% concordance with Mackenzie's Mission gene list. This system enables standardized panel design by providing reliable, automated classification supported by direct evidence.

q-bio.GN↗